¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ¿ëµµ, À¯Çü, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)
Global Autoinjectors Market Size study & Forecast, by Application, Type, End User, and Regional Analysis, 2023-2030
»óǰÄÚµå
:
1462832
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2024³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 200 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀåÀº 2022³â¿¡ ¾à 80¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 16.05% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
ÀÚ±âÁÖ»ç±â´Â ¹Ì¸® ä¿öÁø ÁÖ»ç±â ½Ã½ºÅÛÀ» ÅëÇØ ƯÁ¤ ¾à¹°À» 1ȸºÐ¾¿ Åõ¿©Çϵµ·Ï ¼³°èµÈ ÀÇ·á±â±âÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î ·ù¸¶Æ¼½º °üÀý¿°, ´Ù¹ß¼º °æÈÁõ, ¾Æ³ªÇʶô½Ã½º ¹× Á¤±âÀûÀÎ Áֻ簡 ÇÊ¿äÇÑ ±âŸ ¸¸¼ºÁúȯ°ú °°Àº Áõ»ó¿¡ ´ëÇØ ȯÀÚ°¡ ¾à¹°À» ÀÚ°¡ Åõ¿©ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ¼öµ¿ ¹× ÀÚµ¿ ¸ðµ¨À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ À¯ÇüÀÇ ÀÚ±âÁÖ»ç±â°¡ ÀÖÀ¸¸ç, Æí¸®Çϰí È¿À²ÀûÀÎ ¾à¹°Àü´Þ ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õ, ȯÀÚ ¹× Á¦¾àȸ»ç¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ȯÀÚÀÇ ÆíÀǼº¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¸¸¼ºÁúȯ ¹× »ýȰ½À°üº´ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀüÀÔ´Ï´Ù.
¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2020³â±îÁö ¸¸¼ºÁúȯÀÇ À¯º´·üÀº 57% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ Áß ¾à 60%°¡ ½ÅÈï ½ÃÀå¿¡¼ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Globocan 2020 º¸°í¼¿¡ µû¸£¸é ¸¸¼ºÁúȯÀº Àü ¼¼°è¿¡¼ °¡Àå Å« Àå¾Ö ¹× »ç¸Á ¿øÀÎÀ¸·Î, Àü ¼¼°è¿¡¼ 1,929¸¸ 2,789¸íÀÌ »õ·Î ¾Ï Áø´ÜÀ» ¹Þ¾ÒÀ¸¸ç, ¾Ï °ü·Ã »ç¸ÁÀÚ ¼ö´Â 995¸¸ 8,133¸íÀ̾ú½À´Ï´Ù. ¶ÇÇÑ 2021³â 12¿ù ±¹Á¦´ç´¢º´¿¬¸ÍÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é 20-79¼¼ ¼ºÀÎ ´ç´¢º´ ȯÀÚ´Â ¾à 5¾ï 3,700¸¸ ¸í¿¡ ´ÞÇϸç, 2030³â¿¡´Â 6¾ï 4,300¸¸ ¸í, 2045³â¿¡´Â 7¾ï 8,300¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¶ÇÇÑ ÃÖ±Ù ¿©·¯ ¿¬±¸¿¡ µû¸£¸é ÀÚ°¡ ÁÖ»ç±â·Î ·ù¸¶Æ¼½º °üÀý¿° Ä¡·á¸¦ ¹Þ´Â ȯÀÚÀÇ »ó´ç¼ö°¡ ¿ÜºÎ Åõ¿©¿¡ ÀÇÁ¸Çϴ ȯÀÚº¸´Ù ´õ Æí¾ÈÇÏ°í °á°ú°¡ °³¼±µÈ °ÍÀ¸·Î ³ªÅ¸³µ´Ù°í º¸°íÇß½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå Âü¿©ÀÚµéÀÇ Àû±ØÀûÀÎ ³ë·ÂÀÌ ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù SEVER Life SciencesÀÇ ÀÚȸ»çÀÎ ³ë¸£µñ ÆÄ¸¶(NORDIC PHARMA)´Â ij³ª´Ù º¸°ÇºÎ¿¡ ¸ÞÅ䯮·º¼¼ÀÌÆ® ÀÚµ¿ÁÖ»çÁ¦ ³ë¸£µð¸ÞÆ®(Nordimet)ÀÇ ½Å¾à ½ÂÀÎ ½Åû¼¸¦ Á¦ÃâÇß½À´Ï´Ù. ÁßÁõ Ȱµ¿¼º ·ù¸¶Æ¼½º°üÀý¿°(RA) Ä¡·á ¹× ´ëü¿ä¹ý¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â ¼ºÀÎ ÁßÁõ ³Ä¡¼º °Ç¼± Áõ»ó Á¶ÀýÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°ÀÇ ½ÂÀÎÀÌ ¿¹»óµÊ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ °¡¼Ó鵃 °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±×·¯³ª ´ëü ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼±È£µµ ¹× ±ÔÁ¦ À庮Àº 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß Àü ¼¼°è ÀÏȸ¿ë ÀÚ±âÁÖ»ç±â ½ÃÀåÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ±Ù¼ÒÇÑ Â÷ÀÌ·Î °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå Áö¹è·ÂÀº ±â¼úÀûÀ¸·Î Áøº¸µÈ Á¦Ç°ÀÇ Á¶±â µµÀÔ, ÀϰüµÈ Á¦Ç° ½ÂÀÎ, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó±¹³» »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½Ã۵µ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°øÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
- Á¶»ç ´ë»ó³â
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå ¿ªÇÐ
- ÀÚ±âÁÖ»ç±â ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
- ½ÃÀå ÃËÁø¿äÀÎ
- ȯÀÚÀÇ Æí¸®¼º¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡
- ¸¸¼ºÁúȯ°ú »ýȰ½À°üº´ÀÇ Áõ°¡
- ±â¼úÀÇ Áøº¸
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ´ëü ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼±È£µµ
- ±ÔÁ¦ Àå¾Ö¹°
- ½ÃÀå ±âȸ
- ȯÀÚÀÇ Æí¸®¼º¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡
- ÀÇ·á¿ëǰ¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡
Á¦4Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces ¿µÇ⠺м®
- PEST ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- COVID-19 ¿µÇ⠺м®
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È
Á¦5Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : À¯Çüº°
- ½ÃÀå ½º³À¼ô
- ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- ÀÚ±âÁÖ»ç±â ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- ÀÏȸ¿ë ÀÚ±âÁÖ»ç±â
- Àç»ç¿ë °¡´É ÀÚ±âÁÖ»ç±â
Á¦6Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : ¿ëµµº°
- ½ÃÀå ½º³À¼ô
- ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå, ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- ÀÚ±âÁÖ»ç±â ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- ·ù¸¶Æ¼½º °üÀý¿°
- ´Ù¹ß¼º °æÈÁõ
- ¾Æ³ªÇʶô½Ã½º
- ±âŸ ¿ëµµ
Á¦7Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°
- ½ÃÀå ½º³À¼ô
- ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
- ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
- ÀÚ±âÁÖ»ç±â ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
- ÀçÅÃÀÇ·á
- º´¿ø°ú Áø·á¼Ò
- ±âŸ ÃÖÁ¾»ç¿ëÀÚ
Á¦8Àå ¼¼°èÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå : Áö¿ªº° ºÐ¼®
- ÁÖ¿ä ±¹°¡
- ½ÅÈï ±¹°¡
- ÀÚ±âÁÖ»ç±â ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
- ºÏ¹Ì
- ¹Ì±¹
- À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ¾ÖÇø®ÄÉÀÌ¼Ç ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
- ij³ª´Ù
- À¯·´ ÀÚ±âÁÖ»ç±â ½ÃÀå ½º³À¼ô
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç ÀÚ±âÁÖ»ç±â ½ÃÀå ½º³À¼ô
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀÚ±âÁÖ»ç±â ½ÃÀå ½º³À¼ô
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Dickinson and Company
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍÀÇ °¡¿ë¼º¿¡ µû¸§)
- Á¦Ç° °³¿ä
- ÃÖ±Ù µ¿Çâ
- Abbvie Inc
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Becton, Dickinson and Company
- Biogen Inc
- Eli Lilly and Company
- Novartis AG
- Teva Pharmaceuticals
- Ypsomed AG
Á¦10Àå Á¶»ç ÇÁ·Î¼¼½º
- Á¶»ç ÇÁ·Î¼¼½º
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ÃßÁ¤
- °ËÁõ
- ÃâÆÇ
- Á¶»ç ¼Ó¼º
- Á¶»ç ÀüÁ¦Á¶°Ç
KSA
¿µ¹® ¸ñÂ÷
Global Autoinjectors Market is valued approximately USD 8 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 16.05% over the forecast period 2023-2030. Autoinjectors are medical devices designed to deliver a single dose of a particular medication through a pre-filled syringe system. They are typically used by patients for self-administration of medications, particularly for conditions such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, and other chronic diseases requiring regular injections. The market encompasses various types of autoinjectors, including manual and automated models, and serves healthcare providers, patients, and pharmaceutical companies seeking convenient and efficient drug delivery solutions. The market growth is driven by increasing Demand for Convenience of Patients, rising Incidence of Chronic and Lifestyle Diseases, technological Advancements.
For instance, As per the World Health Organization (WHO), the prevalence of chronic diseases is anticipated to increase by 57% by 2020 , with approximately 60% of this surge expected in emerging markets. Chronic diseases represent the foremost causes of disability and morbidity globally. According to the Globocan 2020 report, there were 19,292,789 new cancer cases diagnosed worldwide, resulting in 9,958,133 cancer-related deaths. Additionally, data from the International Diabetes Federation in December 2021 indicates that diabetes affects around 537 million adults aged 20 to 79. By 2030, the diabetic population is projected to reach 643 million, and by 2045, it is forecasted to climb to 783 million. Furthermore, according to various recent studies, a significant proportion of patients undergoing treatment for rheumatoid arthritis with an autoinjector reported comfort and even demonstrated improved outcomes compared to those relying on external administration. Moreover, market players' proactive initiatives are driving market expansion. For example, in March 2022, NORDIC PHARMA, a SEVER Life Sciences subsidiary, submitted a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet, aimed at treating severe disabling active rheumatoid arthritis (RA) and providing symptomatic control of severe, recalcitrant, disabling psoriasis in adults unresponsive to alternative therapies. The anticipated approval of such medications is poised to accelerate market growth. However, preference for Alternative Drug Delivery Modes, and regulatory Hurdles stifle market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Autoinjectors Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America commands a substantial portion of the global disposable auto-injectors market throughout the forecast period, with expectations for being the fastest-growing region, closely trailed by APAC. The region's market dominance can be attributed to factors such as the early embrace of technologically advanced products, consistent product approvals, and the increasing incidence of chronic diseases, all of which contribute to market expansion.
Major market player included in this report are:
- Dickinson and Company
- Abbvie Inc
- Amgen Inc.
- AstraZeneca Plc
- Bayer AG
- Becton, Dickinson and Company
- Biogen Inc
- Eli Lilly and Company
- Novartis AG
- Teva Pharmaceuticals
- Ypsomed AG
- Abbvie
- Amgen
- AstraZeneca
- Bayer
- Becton
- Biogen
- Eli Lilly
- Novartis
- Teva Pharmaceuticals
- Ypsomed
Recent Developments in the Market:
- In August 2023, Taisho Pharmaceutical obtained FDA approval to produce and distribute the Nanozora(R) 30 mg autoinjector, intended for treating patients with rheumatoid arthritis.
- In May 2023, Boehringer Ingelheim revealed FDA approval for the Cyltezo(R) Pen autoinjector, designed for patients with chronic inflammatory disorders.
- In May 2023, MoonLake partnered with SHL Medical to co-develop an autoinjector for the clinical and commercial distribution of MoonLake's Nanobody(R) sonelokimab.
Global Autoinjectors Market Report Scope:
- Historical Data - 2020 - 2021
- Base Year for Estimation - 2022
- Forecast period - 2023-2030
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Type, Application, End-use, Region
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
- Rheumatoid Arthritis
- Multiple Sclerosis
- Anaphylaxis
- Other Applications
By Application:
- Disposable Autoinjectors
- Reusable Autoinjectors
By End-use:
- Home Care Settings
- Hospital & Clinics
- Other End Users
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1.Executive Summary
- 1.1.Market Snapshot
- 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1.Autoinjectors Market, by Region, 2020-2030 (USD Billion)
- 1.2.2.Autoinjectors Market, by Type, 2020-2030 (USD Billion)
- 1.2.3.Autoinjectors Market, by Application, 2020-2030 (USD Billion)
- 1.2.4.Autoinjectors Market, by End-user, 2020-2030 (USD Billion)
- 1.3.Key Trends
- 1.4.Estimation Methodology
- 1.5.Research Assumption
Chapter 2.Global Autoinjectors Market Definition and Scope
- 2.1.Objective of the Study
- 2.2.Market Definition & Scope
- 2.2.1.Industry Evolution
- 2.2.2.Scope of the Study
- 2.3.Years Considered for the Study
- 2.4.Currency Conversion Rates
Chapter 3.Global Autoinjectors Market Dynamics
- 3.1.Autoinjectors Market Impact Analysis (2020-2030)
- 3.1.1.Market Drivers
- 3.1.1.1.Increasing Demand for Convenience of Patients
- 3.1.1.2.Rising Incidence of Chronic and Lifestyle Diseases
- 3.1.1.3. Technological Advancements
- 3.1.2.Market Challenges
- 3.1.2.1.Preference for Alternative Drug Delivery Modes
- 3.1.2.2.Regulatory Hurdles
- 3.1.3.Market Opportunities
- 3.1.3.1.Increasing demand for the convenience of patients
- 3.1.3.2.Increased demand for medical supplies
Chapter 4.Global Autoinjectors Market Industry Analysis
- 4.1.Porter's 5 Force Model
- 4.1.1.Bargaining Power of Suppliers
- 4.1.2.Bargaining Power of Buyers
- 4.1.3.Threat of New Entrants
- 4.1.4.Threat of Substitutes
- 4.1.5.Competitive Rivalry
- 4.2.Porter's 5 Force Impact Analysis
- 4.3.PEST Analysis
- 4.3.1.Political
- 4.3.2.Economical
- 4.3.3.Social
- 4.3.4.Technological
- 4.3.5.Environmental
- 4.3.6.Legal
- 4.4.Top investment opportunity
- 4.5.Top winning strategies
- 4.6.COVID-19 Impact Analysis
- 4.7.Disruptive Trends
- 4.8.Industry Expert Perspective
- 4.9.Analyst Recommendation & Conclusion
Chapter 5.Global Autoinjectors Market, by Type
- 5.1.Market Snapshot
- 5.2.Global Autoinjectors Market by Type, Performance - Potential Analysis
- 5.3.Global Autoinjectors Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
- 5.4.Autoinjectors Market, Sub Segment Analysis
- 5.4.1.Disposable Autoinjectors
- 5.4.2.Reusable Autoinjectors
Chapter 6.Global Autoinjectors Market, by Application
- 6.1.Market Snapshot
- 6.2.Global Autoinjectors Market by Application, Performance - Potential Analysis
- 6.3.Global Autoinjectors Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
- 6.4.Autoinjectors Market, Sub Segment Analysis
- 6.4.1.Rheumatoid Arthritis
- 6.4.2.Multiple Sclerosis
- 6.4.3.Anaphylaxis
- 6.4.4.Other Applications
Chapter 7.Global Autoinjectors Market, by End-user
- 7.1.Market Snapshot
- 7.2.Global Autoinjectors Market by End-user, Performance - Potential Analysis
- 7.3.Global Autoinjectors Market Estimates & Forecasts by End-user 2020-2030 (USD Billion)
- 7.4.Autoinjectors Market, Sub Segment Analysis
- 7.4.1.Home Care Settings
- 7.4.2.Hospital & Clinics
- 7.4.3.Other End Users
Chapter 8.Global Autoinjectors Market, Regional Analysis
- 8.1.Top Leading Countries
- 8.2.Top Emerging Countries
- 8.3.Autoinjectors Market, Regional Market Snapshot
- 8.4.North America Autoinjectors Market
- 8.4.1.U.S. Autoinjectors Market
- 8.4.1.1.Type breakdown estimates & forecasts, 2020-2030
- 8.4.1.2.Application breakdown estimates & forecasts, 2020-2030
- 8.4.1.3.End-user breakdown estimates & forecasts, 2020-2030
- 8.4.2.Canada Autoinjectors Market
- 8.5.Europe Autoinjectors Market Snapshot
- 8.5.1.U.K. Autoinjectors Market
- 8.5.2.Germany Autoinjectors Market
- 8.5.3.France Autoinjectors Market
- 8.5.4.Spain Autoinjectors Market
- 8.5.5.Italy Autoinjectors Market
- 8.5.6.Rest of Europe Autoinjectors Market
- 8.6.Asia-Pacific Autoinjectors Market Snapshot
- 8.6.1.China Autoinjectors Market
- 8.6.2.India Autoinjectors Market
- 8.6.3.Japan Autoinjectors Market
- 8.6.4.Australia Autoinjectors Market
- 8.6.5.South Korea Autoinjectors Market
- 8.6.6.Rest of Asia Pacific Autoinjectors Market
- 8.7.Latin America Autoinjectors Market Snapshot
- 8.7.1.Brazil Autoinjectors Market
- 8.7.2.Mexico Autoinjectors Market
- 8.8.Middle East & Africa Autoinjectors Market
- 8.8.1.Saudi Arabia Autoinjectors Market
- 8.8.2.South Africa Autoinjectors Market
- 8.8.3.Rest of Middle East & Africa Autoinjectors Market
Chapter 9.Competitive Intelligence
- 9.1.Key Company SWOT Analysis
- 9.2.Top Market Strategies
- 9.3.Company Profiles
- 9.3.1. Dickinson and Company
- 9.3.1.1.Key Information
- 9.3.1.2.Overview
- 9.3.1.3.Financial (Subject to Data Availability)
- 9.3.1.4.Product Summary
- 9.3.1.5.Recent Developments
- 9.3.2. Abbvie Inc
- 9.3.3.Amgen Inc.
- 9.3.4. AstraZeneca Plc
- 9.3.5.Bayer AG
- 9.3.6. Becton, Dickinson and Company
- 9.3.7.Biogen Inc
- 9.3.8.Eli Lilly and Company
- 9.3.9.Novartis AG
- 9.3.10.Teva Pharmaceuticals
- 9.3.11. Ypsomed AG
Chapter 10.Research Process
- 10.1.Research Process
- 10.1.1.Data Mining
- 10.1.2.Analysis
- 10.1.3.Market Estimation
- 10.1.4.Validation
- 10.1.5.Publishing
- 10.2.Research Attributes
- 10.3.Research Assumption
°ü·ÃÀÚ·á